Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Gilead Sciences (GILD) Share Price
Media coverage about Gilead Sciences (NASDAQ:GILD) has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gilead Sciences earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.5221662931845 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
- The IBB Biotechnology ETF: The Drugs You Need? (finance.yahoo.com)
- Benefitting from IBB’s Lower Expense Ratio (finance.yahoo.com)
- After Gilead Sciences, More Biotech M&A? (finance.yahoo.com)
- 3 Reasons Why Gilead Sciences Stock Is a Buy Now (fool.com)
- Is It Premature to Celebrate Gilead Sciences, Inc.’s (GILD) Kite Pharma Momentum? Jefferies Looks Beyond the Recent Bull Rally (finance.yahoo.com)
A number of analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Gilead Sciences in a report on Thursday. They issued an “outperform” rating and a $94.00 target price on the stock. ValuEngine lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 13th. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $96.00 target price (up previously from $86.00) on shares of Gilead Sciences in a report on Wednesday, September 6th. Eleven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $83.79.
Gilead Sciences (NASDAQ:GILD) traded up 0.74% during midday trading on Monday, hitting $82.97. The stock had a trading volume of 7,886,494 shares. The company has a 50-day moving average of $77.36 and a 200-day moving average of $70.29. The stock has a market cap of $108.35 billion, a price-to-earnings ratio of 9.01 and a beta of 1.19. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the prior year, the company earned $3.08 EPS. Gilead Sciences’s revenue was down 8.2% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences will post $8.78 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.
In other news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 466,819 shares of company stock valued at $36,740,240 over the last quarter. 1.30% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-gilead-sciences-gild-share-price.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.